Skip to main content
Erschienen in: Inflammation 1/2010

01.02.2010

Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis

verfasst von: Boris K. Pliyev, Mikhail Yu. Menshikov

Erschienen in: Inflammation | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Soluble form of the urokinase-type plasminogen activator receptor (suPAR) is markedly increased in biological fluids during different inflammatory conditions. It has previously been observed that the highest suPAR concentrations in inflammatory exudates tend to be associated with the presence of high number of neutrophils. Guided by this observation and our recent finding that activated neutrophils release suPAR we investigated whether neutrophils can be a source of suPAR during the inflammatory response in vivo. To address this question we conducted the comparative analysis of neutrophils isolated from the paired samples of synovial fluid (SF) and peripheral blood (PB) of rheumatoid arthritis patients. Freshly isolated SF neutrophils released significantly (p < 0.01) higher amounts of suPAR compared with PB neutrophils. We demonstrated that neutrophils from both sources release predominantly the truncated D2D3 form of suPAR. Migration of formyl peptide receptor-like 1 (FPRL1)-transfected human embryonic kidney (HEK) 293 cells toward the supernatants harvested from in vitro cultured SF neutrophils was significantly diminished when D2D3 form of suPAR was immunodepleted from the supernatants. Taken together, these data demonstrate that neutrophils, first, contribute to or are responsible for the generation of the increased suPAR levels during the inflammatory response and, second, release the chemotactically active form of suPAR that might be involved in the recruitment of formyl peptide receptors-expressing leukocytes into the inflamed tissues.
Literatur
1.
Zurück zum Zitat Ragno, P. 2006. The urokinase receptor: a ligand or a receptor? Cell Mol. Life Sci. 63:1028–1037.CrossRefPubMed Ragno, P. 2006. The urokinase receptor: a ligand or a receptor? Cell Mol. Life Sci. 63:1028–1037.CrossRefPubMed
2.
Zurück zum Zitat Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932–943.CrossRefPubMed Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932–943.CrossRefPubMed
3.
Zurück zum Zitat Beaufort, N., D. Leduc, J. C. Rousselle, V. Magdolen, T. Luther, A. Namane, M. Chignard, and D. Pidard. 2004. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 172:540–549.PubMed Beaufort, N., D. Leduc, J. C. Rousselle, V. Magdolen, T. Luther, A. Namane, M. Chignard, and D. Pidard. 2004. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 172:540–549.PubMed
4.
Zurück zum Zitat Hoyer-Hansen, G., E. Ronne, H. Solberg, N. Behrendt, M. Ploug, L. R. Lund, V. Ellis, and K. Danø. 1992. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267:18224–18229.PubMed Hoyer-Hansen, G., E. Ronne, H. Solberg, N. Behrendt, M. Ploug, L. R. Lund, V. Ellis, and K. Danø. 1992. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267:18224–18229.PubMed
5.
Zurück zum Zitat Andolfo, A., W. R. English, M. Resnati, G. Murphy, F. Blasi, and N. Sidenius. 2002. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemostasis. 88:298–306. Andolfo, A., W. R. English, M. Resnati, G. Murphy, F. Blasi, and N. Sidenius. 2002. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb. Haemostasis. 88:298–306.
6.
Zurück zum Zitat Beaufort, N., D. Leduc, J. C. Rousselle, A. Namane, M. Chignard, and D. Pidard. 2004. Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett. 574:89–94.CrossRefPubMed Beaufort, N., D. Leduc, J. C. Rousselle, A. Namane, M. Chignard, and D. Pidard. 2004. Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett. 574:89–94.CrossRefPubMed
7.
Zurück zum Zitat Montuori, N., V. Visconte, G. Rossi, and P. Ragno. 2005. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93:192–198.PubMed Montuori, N., V. Visconte, G. Rossi, and P. Ragno. 2005. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93:192–198.PubMed
8.
Zurück zum Zitat Wilhelm, O. G., S. Wilhelm, G. M. Escott, V. Lutz, V. Magdolen, M. Schmitt, D. B. Rifkin, E. L. Wilson, H. Graeff, and G. Brunner. 1999. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J. Cell Physiol. 180:225–235.CrossRefPubMed Wilhelm, O. G., S. Wilhelm, G. M. Escott, V. Lutz, V. Magdolen, M. Schmitt, D. B. Rifkin, E. L. Wilson, H. Graeff, and G. Brunner. 1999. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J. Cell Physiol. 180:225–235.CrossRefPubMed
9.
Zurück zum Zitat Pyke, C., J. Eriksen, H. Solberg, B. S. Nielsen, P. Kristensen, L. R. Lund, and K. Danø. 1993. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett. 326:69–74.CrossRefPubMed Pyke, C., J. Eriksen, H. Solberg, B. S. Nielsen, P. Kristensen, L. R. Lund, and K. Danø. 1993. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett. 326:69–74.CrossRefPubMed
10.
Zurück zum Zitat Resnati, M., I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA. 99:1359–1364.CrossRefPubMed Resnati, M., I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA. 99:1359–1364.CrossRefPubMed
11.
Zurück zum Zitat Selleri, C., N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, and P. Ragno. 2005. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 105:2198–2205.CrossRefPubMed Selleri, C., N. Montuori, P. Ricci, V. Visconte, M. V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, and P. Ragno. 2005. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 105:2198–2205.CrossRefPubMed
12.
Zurück zum Zitat de Paulis, A., N. Montuori, N. Prevete, I. Fiorentino, F. W. Rossi, V. Visconte, G. Rossi, G. Marone, and P. Ragno. 2004. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J. Immunol. 173:5739–5748.PubMed de Paulis, A., N. Montuori, N. Prevete, I. Fiorentino, F. W. Rossi, V. Visconte, G. Rossi, G. Marone, and P. Ragno. 2004. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J. Immunol. 173:5739–5748.PubMed
13.
Zurück zum Zitat Sidenius, N., C. F. Sier, and F. Blasi. 2000. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475:52–56.CrossRefPubMed Sidenius, N., C. F. Sier, and F. Blasi. 2000. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 475:52–56.CrossRefPubMed
14.
Zurück zum Zitat Mizukami, I. F., N. E. Faulkner, M. R. Gyetko, R. G. Sitrin, and R. F. Todd 3rd. 1995. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 86:203–211.PubMed Mizukami, I. F., N. E. Faulkner, M. R. Gyetko, R. G. Sitrin, and R. F. Todd 3rd. 1995. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 86:203–211.PubMed
15.
Zurück zum Zitat Wittenhagen, P., G. Kronborg, N. Weis, H. Nielsen, N. Obel, S. S. Pedersen, and J. Eugen-Olsen. 2004. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin. Microbiol. Infect. 10:409–415.CrossRefPubMed Wittenhagen, P., G. Kronborg, N. Weis, H. Nielsen, N. Obel, S. S. Pedersen, and J. Eugen-Olsen. 2004. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin. Microbiol. Infect. 10:409–415.CrossRefPubMed
16.
Zurück zum Zitat Perch, M., P. Kofoed, T. K. Fischer, F. Có, L. Rombo, P. Aaby, and J. Eugen-Olsen. 2004. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol. 26:207–211.CrossRefPubMed Perch, M., P. Kofoed, T. K. Fischer, F. Có, L. Rombo, P. Aaby, and J. Eugen-Olsen. 2004. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol. 26:207–211.CrossRefPubMed
17.
Zurück zum Zitat Ostrowski, S. R., P. Ravn, G. Hoyer-Hansen, H. Ullum, and A. B. Andersen. 2006. Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy. Scand. J. Infect. Dis. 38:1028–1032.CrossRefPubMed Ostrowski, S. R., P. Ravn, G. Hoyer-Hansen, H. Ullum, and A. B. Andersen. 2006. Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy. Scand. J. Infect. Dis. 38:1028–1032.CrossRefPubMed
18.
Zurück zum Zitat Slot, O., N. Brünner, H. Locht, P. Oxholm, and R. W. Stephens. 1999. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 58:488–492.CrossRefPubMed Slot, O., N. Brünner, H. Locht, P. Oxholm, and R. W. Stephens. 1999. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 58:488–492.CrossRefPubMed
19.
Zurück zum Zitat Kasperska-Zajac, A., and B. Rogala. 2005. Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome. Inflammation. 29:90–93.CrossRefPubMed Kasperska-Zajac, A., and B. Rogala. 2005. Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome. Inflammation. 29:90–93.CrossRefPubMed
20.
Zurück zum Zitat de Bock, C. E., and Y. Wang. 2004. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24:13–39.CrossRefPubMed de Bock, C. E., and Y. Wang. 2004. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24:13–39.CrossRefPubMed
21.
Zurück zum Zitat Chu, S. C., S. F. Yang, K. H. Lue, Y. S. Hsieh, T. Y. Hsiao, and K. H. Lu. 2006. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J. Rheumatol. 33:311–317.PubMed Chu, S. C., S. F. Yang, K. H. Lue, Y. S. Hsieh, T. Y. Hsiao, and K. H. Lu. 2006. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J. Rheumatol. 33:311–317.PubMed
22.
Zurück zum Zitat Ostergaard, C., T. Benfield, J. D. Lundgren, and J. Eugen-Olsen. 2004. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand. J. Infect. Dis. 36:14–19.CrossRefPubMed Ostergaard, C., T. Benfield, J. D. Lundgren, and J. Eugen-Olsen. 2004. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand. J. Infect. Dis. 36:14–19.CrossRefPubMed
23.
Zurück zum Zitat Pliyev, B. K. 2009. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol. Cell. Biochem. 321:111–122.CrossRefPubMed Pliyev, B. K. 2009. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol. Cell. Biochem. 321:111–122.CrossRefPubMed
24.
Zurück zum Zitat Pliyev, B. K. 2008. Chemotactically active proteins of neutrophils. Biochemistry (Mosc.). 73:970–984.CrossRef Pliyev, B. K. 2008. Chemotactically active proteins of neutrophils. Biochemistry (Mosc.). 73:970–984.CrossRef
25.
Zurück zum Zitat Böyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. 97:77–89. Böyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. 97:77–89.
26.
Zurück zum Zitat Sengeløv, H., P. Follin, L. Kjeldsen, K. Lollike, C. Dahlgren, and N. Borregaard. 1995. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. J. Immunol. 154:4157–4165.PubMed Sengeløv, H., P. Follin, L. Kjeldsen, K. Lollike, C. Dahlgren, and N. Borregaard. 1995. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. J. Immunol. 154:4157–4165.PubMed
27.
Zurück zum Zitat Theilgaard-Mönch, K., S. Knudsen, P. Follin, and N. Borregaard. 2004. The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J. Immunol. 172:7684–7693.PubMed Theilgaard-Mönch, K., S. Knudsen, P. Follin, and N. Borregaard. 2004. The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J. Immunol. 172:7684–7693.PubMed
28.
Zurück zum Zitat Coldren, C. D., J. A. Nick, K. R. Poch, M. D. Woolum, B. W. Fouty, J. M. O’Brien, M. P. Gruber, M. R. Zamora, D. Svetkauskaite, D. A. Richter, Q. He, J. S. Park, K. H. Overdier, E. Abraham, and M. W. Geraci. 2006. Functional and genomic changes induced by alveolar transmigration in human neutrophils. Am. J. Physiol. Lung Cell. Mol. Physiol. 291:L1267–L1276.CrossRefPubMed Coldren, C. D., J. A. Nick, K. R. Poch, M. D. Woolum, B. W. Fouty, J. M. O’Brien, M. P. Gruber, M. R. Zamora, D. Svetkauskaite, D. A. Richter, Q. He, J. S. Park, K. H. Overdier, E. Abraham, and M. W. Geraci. 2006. Functional and genomic changes induced by alveolar transmigration in human neutrophils. Am. J. Physiol. Lung Cell. Mol. Physiol. 291:L1267–L1276.CrossRefPubMed
29.
Zurück zum Zitat Kuhns, D. B., D. A. Long Priel, and J. I. Gallin. 1995. Loss of L-selectin (CD62L) on human neutrophils following exudation in vivo. Cell. Immunol. 164:306–310.CrossRefPubMed Kuhns, D. B., D. A. Long Priel, and J. I. Gallin. 1995. Loss of L-selectin (CD62L) on human neutrophils following exudation in vivo. Cell. Immunol. 164:306–310.CrossRefPubMed
30.
Zurück zum Zitat Lopez, S., L. Halbwachs-Mecarelli, P. Ravaud, G. Bessou, M. Dougados, and F. Porteu. 1995. Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis. Clin. Exp. Immunol. 101:25–32.PubMedCrossRef Lopez, S., L. Halbwachs-Mecarelli, P. Ravaud, G. Bessou, M. Dougados, and F. Porteu. 1995. Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis. Clin. Exp. Immunol. 101:25–32.PubMedCrossRef
31.
Zurück zum Zitat Hönig, M., H. H. Peter, P. Jantscheff, and F. Grunert. 1999. Synovial PMN show a coordinated up-regulation of CD66 molecules. J. Leukoc. Biol. 66:429–436.PubMed Hönig, M., H. H. Peter, P. Jantscheff, and F. Grunert. 1999. Synovial PMN show a coordinated up-regulation of CD66 molecules. J. Leukoc. Biol. 66:429–436.PubMed
32.
Zurück zum Zitat Pillinger, M. H., and S. B. Abramson. 1995. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. North. Am. 21:691–714.PubMed Pillinger, M. H., and S. B. Abramson. 1995. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. North. Am. 21:691–714.PubMed
33.
Zurück zum Zitat Edwards, S. W., and M. B. Hallett. 1997. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today. 18:320–324.CrossRefPubMed Edwards, S. W., and M. B. Hallett. 1997. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today. 18:320–324.CrossRefPubMed
34.
Zurück zum Zitat Behrendt, N., E. Rønne, M. Ploug, T. Petri, D. Løber, L. S. Nielsen, W. D. Schleuning, F. Blasi, E. Appella, and K. Danø. 1990. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265:6453–6460.PubMed Behrendt, N., E. Rønne, M. Ploug, T. Petri, D. Løber, L. S. Nielsen, W. D. Schleuning, F. Blasi, E. Appella, and K. Danø. 1990. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J. Biol. Chem. 265:6453–6460.PubMed
35.
Zurück zum Zitat Bae, Y. S., H. Y. Lee, E. J. Jo, J. I. Kim, H. K. Kang, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2004. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol. 173:607–614.PubMed Bae, Y. S., H. Y. Lee, E. J. Jo, J. I. Kim, H. K. Kang, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2004. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol. 173:607–614.PubMed
36.
Zurück zum Zitat Fleit, H. B., C. D. Kobasiuk, C. Daly, R. Furie, P. C. Levy, and R. O. Webster. 1992. A soluble form of Fc gamma RIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood. 79:2721–2728.PubMed Fleit, H. B., C. D. Kobasiuk, C. Daly, R. Furie, P. C. Levy, and R. O. Webster. 1992. A soluble form of Fc gamma RIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood. 79:2721–2728.PubMed
37.
Zurück zum Zitat Fridman, W. H., J. L. Teillaud, C. Bouchard, C. Teillaud, A. Astier, E. Tartour, J. Galon, C. Mathiot, and C. Sautès. 1993. Soluble Fc gamma receptors. J. Leukoc. Biol. 54:504–512.PubMed Fridman, W. H., J. L. Teillaud, C. Bouchard, C. Teillaud, A. Astier, E. Tartour, J. Galon, C. Mathiot, and C. Sautès. 1993. Soluble Fc gamma receptors. J. Leukoc. Biol. 54:504–512.PubMed
38.
Zurück zum Zitat Yang, D., Q. Chen, A. P. Schmidt, G. M. Anderson, J. M. Wang, J. Wooters, J. J. Oppenheim, and O. Chertov. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069–1074.CrossRefPubMed Yang, D., Q. Chen, A. P. Schmidt, G. M. Anderson, J. M. Wang, J. Wooters, J. J. Oppenheim, and O. Chertov. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069–1074.CrossRefPubMed
39.
Zurück zum Zitat Mustjoki, S., N. Sidenius, C. F. Sier, F. Blasi, E. Elonen, R. Alitalo, and A. Vaheri. 2000. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 60:7126–7132.PubMed Mustjoki, S., N. Sidenius, C. F. Sier, F. Blasi, E. Elonen, R. Alitalo, and A. Vaheri. 2000. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 60:7126–7132.PubMed
40.
Zurück zum Zitat Resnati, M., I. Pallavicini, R. Daverio, N. Sidenius, P. Bonini, and F. Blasi. 2006. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J. Immunol. Methods. 308:192–202.CrossRefPubMed Resnati, M., I. Pallavicini, R. Daverio, N. Sidenius, P. Bonini, and F. Blasi. 2006. Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR). J. Immunol. Methods. 308:192–202.CrossRefPubMed
41.
Zurück zum Zitat Miyata, J., K. Tani, K. Sato, S. Otsuka, T. Urata, B. Lkhagvaa, C. Furukawa, N. Sano, and S. Sone. 2007. Cathepsin G: the significance in rheumatoid arthritis as a monocyte chemoattractant. Rheumatol. Int. 27:375–382.CrossRefPubMed Miyata, J., K. Tani, K. Sato, S. Otsuka, T. Urata, B. Lkhagvaa, C. Furukawa, N. Sano, and S. Sone. 2007. Cathepsin G: the significance in rheumatoid arthritis as a monocyte chemoattractant. Rheumatol. Int. 27:375–382.CrossRefPubMed
42.
Zurück zum Zitat Auer, J., M. Bläss, H. Schulze-Koops, S. Russwurm, T. Nagel, J. R. Kalden, M. Röllinghoff, and H. U. Beuscher. 2007. Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res. Ther. 9:R94.CrossRefPubMed Auer, J., M. Bläss, H. Schulze-Koops, S. Russwurm, T. Nagel, J. R. Kalden, M. Röllinghoff, and H. U. Beuscher. 2007. Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res. Ther. 9:R94.CrossRefPubMed
43.
Zurück zum Zitat Hatano, Y., T. Kasama, H. Iwabuchi, R. Hanaoka, H. T. Takeuchi, L. Jing, Y. Mori, K. Kobayashi, M. Negishi, H. Ide, and M. Adachi. 1999. Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. 58:297–302.CrossRefPubMed Hatano, Y., T. Kasama, H. Iwabuchi, R. Hanaoka, H. T. Takeuchi, L. Jing, Y. Mori, K. Kobayashi, M. Negishi, H. Ide, and M. Adachi. 1999. Macrophage inflammatory protein 1 alpha expression by synovial fluid neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. 58:297–302.CrossRefPubMed
Metadaten
Titel
Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis
verfasst von
Boris K. Pliyev
Mikhail Yu. Menshikov
Publikationsdatum
01.02.2010
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2010
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9152-0

Weitere Artikel der Ausgabe 1/2010

Inflammation 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.